Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.

Navega Therapeutics, a biotechnology company developing epigenetic gene therapies, today announced the receipt of a $4M Translational Science grant from CIRM for the relief of neuropathic pain.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Federal officials have approved new pain medication Journavx, designed to offer short-term pain relief without the addiction and overdose risks associated with opioids like Vicodin and OxyContin. The ...

The US Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...